News

Cullinan Therapeutics and Partners Showcase Breakthrough Cancer Trial Findings

Cullinan Therapeutics and Partners Showcase Breakthrough Cancer Trial Findings

Cullinan Therapeutics and Partners Showcase Breakthrough Cancer Trial Findings

CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J. – Cullinan Therapeutics, Inc. (NASDAQ: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. have recently reported promising findings from the pivotal Phase 2b cohorts of the REZILIENT1 trial. This important clinical trial focuses on zipalertinib, a novel treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) specifically harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These exciting results are slated for presentation on June 1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting during an oral presentation session dedicated to non-small cell lung cancer.

The Urgent Need for Effective Treatment Options

Dr. Helena A. Yu, Thoracic Medical Oncologist and Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center, emphasized the urgency for targeted therapies that patients with EGFR ex20ins NSCLC require. As many struggle against this aggressive cancer type, the trial's findings bring hope, indicating that zipalertinib may present a viable new oral treatment option for individuals whose cancer has progressed despite prior therapies.

Results from REZILIENT1 Trial

As of the latest data cutoff, 244 patients had been enrolled in the REZILIENT1 trial and received at least one dose of 100 mg zipalertinib. Analysis of the overall efficacy population revealed noteworthy efficacy outcomes. The key findings include:

  • Overall Efficacy Population: Among 176 patients assessed, the confirmed overall objective response rate (ORR) stood at 35%, with a median duration of response (mDOR) of 8.8 months.
  • Patients Who Received Prior Platinum-Based Chemotherapy: For 125 of these participants, the ORR was 40%, with an mDOR of 8.8 months, showing consistency with earlier trials.
  • Patients with Amivantamab and Chemotherapy: In those treated previously with both chemotherapy and amivantamab (30 patients), the ORR was 30% with an impressive mDOR of 14.7 months.
  • Patients with Brain Metastases: Among 68 patients with prior brain metastases included in the study, the ORR was 31%, and the mDOR was 8.3 months.

Understanding the Safety Profile

The safety analysis included all 244 patients who received at least one dose of zipalertinib. Results indicated a manageable safety profile, with most treatment-related adverse events (TRAEs) classified as grade 1 or 2. Common TRAEs were reported as:

  • Paronychia (38.5%)
  • Rash (30.3%)
  • Dermatitis acneiform (24.6%)
  • Dry skin (24.6%)
  • Diarrhea (21.7%)
  • Stomatitis (20.1%)

Furthermore, the most significant grade ?3 TRAEs included anemia (7%) and pneumonitis, along with rash (2.5%, each). These safety findings affirm that zipalertinib can be administered effectively to patients who have undergone various treatments.

Insights on Zipalertinib and Its Development

Zipalertinib (development code: CLN-081/TAS6417) represents a significant advancement in targeted therapies, engineered to inhibit EGFR variants, particularly those with exon 20 insertion mutations while preserving the wild-type EGFR function. This selective targeting positions zipalertinib as a pioneering irreversible EGFR inhibitor tailored for patients with non-small cell lung cancer, focusing on optimizing treatment outcomes for this specific genetic alteration. Its development is notably bolstered by the Breakthrough Therapy Designation granted by the FDA, highlighting the treatment's potential.

Collaborative Commitment to Innovation

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology are actively collaborating in the development of zipalertinib, combining their unique strengths and expertise to offer innovative solutions for oncology patients. The collaborative effort underscores a shared commitment to improving the lives of cancer patients through advanced research and the intersection of clinical excellence and patient-centric approaches.

Frequently Asked Questions

What is the REZILIENT1 trial?

The REZILIENT1 trial is a Phase 1/2 clinical study evaluating the efficacy and safety of zipalertinib in patients with advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

What were the efficacy results of the trial?

The trial showed a confirmed overall objective response rate of 35% with a median duration of response of 8.8 months in the overall efficacy population.

How safe is zipalertinib?

Zipalertinib demonstrated a generally manageable safety profile, with most treatment-related adverse events being mild (grade 1 or 2).

What is the primary focus of zipalertinib?

Zipalertinib specifically targets EGFR variants with exon 20 insertion mutations in non-small cell lung cancer.

Why is the REZILIENT1 trial significant?

The trial offers promising results for a treatment option that could improve the lives of patients with limited alternatives after prior therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 94

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 130

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 29

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 72

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 0

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 10

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 50

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading

Top 5 Most Recently Viewed Articles

GENFIT Achieves Milestone with EU Approval for Iqirvo®

Updated Category News Views 121

GENFIT Secures EU Approval for Iqirvo® GENFIT, a leading biopharmaceutical firm, has proudly announced that it received conditional approval from the European Commission for its medication Iqirvo® (elafibranor) at an 80mg dosage. This remarkable treatment is tailored for adults dealing with Primary Biliary Cholangitis (PBC) and is intended to be used in conjunction with...

Continue Reading
Yellow Pages Limited Q3 2025: Financial Highlights and Future Outlook

Updated Category News Views 252

Overview of Yellow Pages Limited's Financial Performance Yellow Pages Limited (TSX: Y), a notable player in the Canadian digital media and marketing landscape, has recently announced its financial results for the third quarter of 2025. The company showcases solid profitability and remains committed to its growth strategies. During this quarter, Yellow Pages Limited...

Continue Reading
Prosus's Major Move: Acquiring Despegar for $1.7 Billion

Updated Category News Views 230

Prosus's Strategic Acquisition of Despegar Prosus (OTC: PROSF) NV, recognized as a leading global technology investor, has revealed its intention to acquire Despegar (NYSE: DESP), a prominent online travel agency in Latin America, for an impressive sum of $1.7 billion. Under the terms of this agreement, shareholders of Despegar will benefit from a payment of $19.50 per...

Continue Reading
Discover Roof AI: Revolutionizing Roof Visualization for All

Updated Category News Views 207

Introducing Roof AI: The Future of Roof Visualization Roof AI has emerged as an innovative solution, especially after the successful launches of Remodel AI and Paint AI. It's designed to bring a significant transformation in how homeowners, contractors, designers, and roofing manufacturers visualize roofs before making any decisions. Whether you're planning a roof...

Continue Reading
Associa Celebrates Employee Recognition in National Awards

Updated Category News Views 240

Associa's Remarkable Achievement in Workplace Recognition Associa, a leader in community association management, proudly shares its recognition as a 2024 winner of the prestigious Best and Brightest Companies to Work for in the Nation. This accolade marks an impressive sixth recognition for the company, a testament to its unwavering dedication to cultivating an innovative...

Continue Reading